Isis gets $3m from GSK for PhI trial of antiviral

2nd December 2013

Isis Pharmaceuticals has kicked off a Phase I study of an antiviral candidate partnered with GSK, triggering a $3 million milestone payment from the latter firm.

Details are somewhat scant, with the firms saying only that the antisense drug ISIS-GSK3Rx has been designed – with Isis’ discovery platform – to inhibit the production of an undisclosed target to treat a common viral infection.

Read the source article at

Leave a Reply

Your email address will not be published.

− 4 = 2

« back to posts